ARTICLE | Clinical News
Galeterone: Phase III started
July 20, 2015 7:00 AM UTC
Tokai began the open-label, international Phase III ARMOR3-SV trial to compare 2,550 mg oral galeterone once daily vs. once-daily oral Xtandi enzalutamide in 148 treatment-naive patients whose tumors...